Home >> MARKETPLACE >> SeraCare partners with AccuRef, Bayer

SeraCare partners with AccuRef, Bayer

Print Friendly, PDF & Email

January 2019—SeraCare Life Sciences announced an exclusive partnership with AccuRef Diagnostics, a division of Applied StemCell, to market and sell AccuRef’s portfolio of CRISPR-engineered cell line reference materials alongside the Seraseq portfolio of NGS cancer products. Customers will be able to purchase AccuRef cancer reference materials directly from SeraCare worldwide, with the exception of China, beginning in January.

SeraCare announced in a separate release the commercial launch of an expanded neurotrophic tropomyosin receptor kinase RNA fusion reference material panel developed in a partnership with Bayer. The Seraseq NTRK FFPE RNA reference material contains 15 clinically significant NTRK RNA fusions across NTRK1, NTRK2, and NTRK3 genes and are to be used by clinical laboratories looking to validate their detection by next-generation sequencing methods. The RNA fusions are present inside SeraCare’s reference cell line GM24385 and formalin fixed and paraffin embedded to represent typical processed tumor sections.

SeraCare Life Sciences, 301-591-8200


Check Also

Fusion RNA assay reference standards, 4/17

April 2017—SeraCare Life Sciences launched its Seraseq Fusion RNA Mix v2 and Seraseq FFPE Fusion RNA Reference Material v2. The highly multiplexed mixes include 15 clinically actionable fusion RNA partners. Two formats are offered—purified nucleic acid (Fusion RNA Mix) and formalin-fixed, paraffin-embedded tissue slices (FFPE Fusion RNA Reference material).